Список проголосовавших за комментарий " On The Wires<ul><li>Lianluo Smart Limited (<strong>LLIT</strong>) announced that it has received the design patent certificate for the DHR 998 Plus Wearable Sleep Apnea Syndrome Diagnostic Watch, which is a main product under the business of the Company's medical wearable device sector.</li><li>Natera (<strong>NTRA</strong>) announced the termination of a distribution agreement with Bioreference Laboratories. With the ending of the distribution agreement, Natera intends to promote Panorama directly to clinicians, who previously ordered this test through Bio-Reference. Natera also plans to promote its Horizon carrier screen test to these clinicians, which it had not done previously.</li><li> Lionsgate (<strong>LGF.A</strong>, <strong>LGF.B</strong>) announced that it has invested in leading eSports franchise Immortals.</li><li>Merck (<strong>MKGAY</strong>) announced the expansion of its end-to-end biodevelopment centers to meet increasing customer demand for its turnkey portfolio of bioprocessing products, manufacturing capabilities and industry leading technological expertise.</li><li>Majesco Entertainment (<strong>COOL</strong>) changes name to 'PolarityTE, Inc.' effective January 11; ticker unchanged. </li><li>Wix.com (<strong>WIX</strong>) announced its integration with Square to give Wix merchants and entrepreneurs in North America a new way to accept online and in-person credit card payments.</li><li>RedHill Biopharma (<strong>RDHL</strong>) announced the first group of subjects have been dosed in a single-dose three-way crossover pharmacokinetic study with RHB-105 versus the active comparators in the confirmatory Phase III study and in a food-effect study with RHB-105 in healthy volunteers. The confirmatory Phase III study with RHB-105 for H. pylori infection is planned to be initiated, subject to regulatory approvals and completion of the supportive pharmacokinetic program, by April of this year. Subject to a successful outcome, the confirmatory Phase III study and the supportive pharmacokinetic program are expected to complete the package required for a U.S. NDA for RHB-105.</li><li>InVivo Therapeutics (<strong>NVIV</strong>) announced that Rhode Island Hospital in Providence, RI has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury.</li></ul>"